Kite Pharma Inc., of Santa Monica, Calif., reported that the European Commission has conferred orphan status on KTE-C19 for the treatment of diffuse large B-cell lymphoma. Kite has filed an investigational new drug application to conduct a phase I/II trial for KTE-C19 with the FDA, which has also granted the candidate orphan status.